Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript Summary
Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript Summary
Free cash flow robust at $922 million; net debt to EBITDA ratio improved to three.The following is a summary of the Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript:
以下是梯瓦製藥業有限公司（TEVA）2024年第三季度業績會成績單摘要：
Financial Performance:
財務表現:
Q3 2024 revenue reached $4.3 billion, up 15% year-on-year; adjusted EBITDA at $1.3 billion, up 17%.
Free cash flow robust at $922 million; net debt to EBITDA ratio improved to three.
2024年第三季度營業收入達到43億美元，同比增長15％；調整後的EBITDA爲13億美元，同比增長17%。
自由現金流強勁，達到92200萬美元；淨債務與EBITDA比率改善至3。
Business Progress:
業務進展：
Advanced 'pivot to growth' strategy with strong performance in innovative products like AUSTEDO, expected to reach $1.6 billion in revenue.
Significant progress in biosimilars portfolio, with a Prolia biosimilar review expected soon in US and EU.
採取強大的「轉向增長」戰略，創新產品如AUSTEDO表現強勁，預計達到16億美元營業收入。
生物仿製藥組合取得重大進展，預計不久將在美國和歐盟對Prolia類似物進行審查。
Opportunity:
機會：
Expansion in the biosimilars market targeting nearly $60 billion in brand value; UZEDY's revenue guidance increased to $100 million.
Strategic partnership with mAbxience enhances oncology biosimilars portfolio and market reach.
在生物仿製藥市場擴張，目標是接近600億美元的品牌價值；UZEDY的營收指引上調至10000萬美元。
與mAbxience的戰略合作增強了腫瘤生物仿製藥組合和市場覆蓋。
Risk:
風險：
Uncertainties in AI service growth and market acceptance of new drug formulations amid competitive pressures.
Regulatory and market pressures on generic drug pricing pose ongoing financial challenges.
在競爭壓力下，人工智能服務增長和市場對新藥配方的接受度存在不確定性。
監管和市場壓力對於普通藥物定價構成持續的財務挑戰。
Financial Performance:
財務表現:
Teva Pharmaceutical reported strong Q3 2024 results with revenues increasing to $4.3 billion, up 15% year-on-year.
Adjusted EBITDA rose to $1.3 billion, up 17%.
Earnings per share (EPS) increased by 16%.
Free cash flow was robust at $922 million, and the net debt to EBITDA ratio improved to three, underscoring effective debt management.
Revenue growth was driven by both innovative and generic product segments, with notable performance in regions across the globe.
梯瓦製藥報告2024年第三季度業績強勁，營業收入增至43億美元，同比增長15%。
調整後的EBITDA增至13億美元，同比增長17%。
每股收益（EPS）增長了16%。
自由現金流爲92200萬美元，淨債務與息稅折舊攤銷前利潤（EBITDA）比率改善至3，彰顯有效的債務管理。
營業收入增長受創新和仿製品部門驅動，在全球各地區表現顯著。
Business Progress:
業務進展：
Teva is advancing its 'pivot to growth' strategy, focusing on innovation, creating a sustainable generics powerhouse, and strategic business focus.
Strong growth noted in innovative products AUSTEDO, AJOVY, and UZEDY, with AUSTEDO expected to reach $1.6 billion in full-year revenue.
Significant progress in the biosimilars portfolio, including a Prolia biosimilar expected to be reviewed by US and EU regulators in the next year.
Continued robust performance in the generic drug segment, driven by strategic product launches and effective supply chain management.
梯瓦正在推進其「轉向增長」策略，專注於創新，打造可持續的仿製藥強者和戰略業務重點。
創新產品AUSTEDO、AJOVY和UZEDY表現強勁，其中AUSTEDO預計全年營業收入將達到16億美元。
生物類似藥品組合取得重大進展，包括一種Prolia類似物預計將在明年被美國和歐盟監管機構審查。
在仿製藥品領域持續強勁表現，其驅動因素爲戰略性產品推出和有效的供應鏈管理。
Opportunities:
機會：
Innovations in Teva's product pipeline provide opportunities for significant growth, particularly with promising results expected from ongoing clinical trials.
Expansion in the biosimilars market, targeting nearly $60 billion in brand value, offers potential for substantial revenue growth.
Increased guidance for UZEDY's full-year revenue up to $100 million reflects strong market adoption and demand.
Strategic partnerships, such as the collaboration with mAbxience on oncology biosimilars, enhance Teva's portfolio and market reach.
梯瓦產品管道的創新爲公司帶來了重大增長機會，尤其是由於正在進行的臨床試驗預計將取得令人期待的結果。
生物仿製藥市場的擴張，以近600億美元的品牌價值爲目標，爲營業收入的實質性增長提供了潛在機會。
UZEDY年度營業收入預期增加至10000萬美元，反映了市場對其的強勁認可和需求。
諸如與mAbxience在腫瘤生物仿製藥領域的合作等戰略伙伴關係，增強了梯瓦的產品組合和市場覆蓋範圍。
Risks:
風險：
The launch performance and future growth potential for Teva's AI services, including the long-acting Olanzapine formulations, may introduce uncertainties, depending on clinical trial outcomes and market acceptance amid competitive pressures.
Regulatory and market pressures on generic drug pricing continue to pose financial challenges, requiring ongoing innovation and operational efficiency to maintain profitability.
梯瓦AI服務的推出表現和未來增長潛力，包括長效奧氮平配方，可能會帶來不確定性，取決於臨床試驗結果和市場接受度，同時還要應對競爭壓力。
對於普通藥品定價方面的監管和市場壓力繼續帶來財務挑戰，需要持續創新和提高運營效率以保持盈利能力。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
